A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity
Yufan Jian,1,2,* Meina Zhao,1,2,* Jinyi Cao,1,* Tingting Fan,1 Wei Bu,1 Yang Yang,3 Weiwei Li,1 Wei Zhang,1 Yi Qiao,1 Jingwen Wang,1 Aidong Wen1,2 1Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, People’s Republic of China; 2College...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-06-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-gastric-cancer-peptide-gx1-modified-nano-lipid-carriers-encapsulatin-peer-reviewed-article-DDDT |
| _version_ | 1818504907237359616 |
|---|---|
| author | Jian Y Zhao M Cao J Fan T Bu W Yang Y Li W Zhang W Qiao Y Wang J Wen A |
| author_facet | Jian Y Zhao M Cao J Fan T Bu W Yang Y Li W Zhang W Qiao Y Wang J Wen A |
| author_sort | Jian Y |
| collection | DOAJ |
| description | Yufan Jian,1,2,* Meina Zhao,1,2,* Jinyi Cao,1,* Tingting Fan,1 Wei Bu,1 Yang Yang,3 Weiwei Li,1 Wei Zhang,1 Yi Qiao,1 Jingwen Wang,1 Aidong Wen1,2 1Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, People’s Republic of China; 2College of Pharmacy, Shannxi University of Chinese Medicine, Xianyang 712046, People’s Republic of China; 3Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tingting Fan; Aidong WenDepartment of Pharmacy, Xijing Hospital, The Air Force Military Medical University, Xi’an 710032, People’s Republic of ChinaEmail fanting0427@163.com; adwen-2004@hotmail.comAim: The aim of this study was to develop a GX1-modified nanostructured lipid carrier (NLCs) and to evaluate its ability to improve the anti-gastric cancer tumor effects of paclitaxel (PTX).Main Methods: The GX1-modified NLCs were synthesized and loaded with PTX (GX1-PTX-NLCs) by emulsion solvent evaporation technique. The anti-tumor activity and pharmacodynamics were then evaluated by in vitro cell studies and animal experiments.Key Findings: The GX1-modified NLCs were successfully synthesized and confirmed by 1H NMR and MALDI-TOF-MS. PTX-loaded NLCs produced particles with average size distribution less than or equal to 222 nm and good drug loading and entrapment efficiency. In vitro studies demonstrated that GX1-PTX-NLCs had a more obvious inhibitory effect on Co-HUVEC cells than PTX and unmodified PTX-NLCs. The cellular uptake results also showed that GX1-PTX-NLCs were largely concentrated in Co-HUVEC cells, and the uptake rates of GX1-PTX-NLCs in Co-HUVEC were higher than those of the free drug and the PTX-NLC. In vivo studies demonstrated that GX1-PTX-NLCs possess strong anti-tumor effect and showed higher tumor growth inhibition and lower toxicity in nude mice.Significance: These results suggest that GX1-modified NLCs enhanced the anti-tumor activity of PTX and reduced its toxicity effectively. GX1-PTX-NLCs may be considered as a potent drug delivery system for therapy of gastric cancer.Keywords: gastric cancer, paclitaxel, nano-lipid carriers, gastric cancer peptide, anti-tumor activity |
| first_indexed | 2024-12-10T21:43:34Z |
| format | Article |
| id | doaj.art-3e8b4a89832d445ca9c5a480e2eda12c |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-10T21:43:34Z |
| publishDate | 2020-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-3e8b4a89832d445ca9c5a480e2eda12c2022-12-22T01:32:26ZengDove Medical PressDrug Design, Development and Therapy1177-88812020-06-01Volume 142355237054495A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor ActivityJian YZhao MCao JFan TBu WYang YLi WZhang WQiao YWang JWen AYufan Jian,1,2,* Meina Zhao,1,2,* Jinyi Cao,1,* Tingting Fan,1 Wei Bu,1 Yang Yang,3 Weiwei Li,1 Wei Zhang,1 Yi Qiao,1 Jingwen Wang,1 Aidong Wen1,2 1Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, People’s Republic of China; 2College of Pharmacy, Shannxi University of Chinese Medicine, Xianyang 712046, People’s Republic of China; 3Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tingting Fan; Aidong WenDepartment of Pharmacy, Xijing Hospital, The Air Force Military Medical University, Xi’an 710032, People’s Republic of ChinaEmail fanting0427@163.com; adwen-2004@hotmail.comAim: The aim of this study was to develop a GX1-modified nanostructured lipid carrier (NLCs) and to evaluate its ability to improve the anti-gastric cancer tumor effects of paclitaxel (PTX).Main Methods: The GX1-modified NLCs were synthesized and loaded with PTX (GX1-PTX-NLCs) by emulsion solvent evaporation technique. The anti-tumor activity and pharmacodynamics were then evaluated by in vitro cell studies and animal experiments.Key Findings: The GX1-modified NLCs were successfully synthesized and confirmed by 1H NMR and MALDI-TOF-MS. PTX-loaded NLCs produced particles with average size distribution less than or equal to 222 nm and good drug loading and entrapment efficiency. In vitro studies demonstrated that GX1-PTX-NLCs had a more obvious inhibitory effect on Co-HUVEC cells than PTX and unmodified PTX-NLCs. The cellular uptake results also showed that GX1-PTX-NLCs were largely concentrated in Co-HUVEC cells, and the uptake rates of GX1-PTX-NLCs in Co-HUVEC were higher than those of the free drug and the PTX-NLC. In vivo studies demonstrated that GX1-PTX-NLCs possess strong anti-tumor effect and showed higher tumor growth inhibition and lower toxicity in nude mice.Significance: These results suggest that GX1-modified NLCs enhanced the anti-tumor activity of PTX and reduced its toxicity effectively. GX1-PTX-NLCs may be considered as a potent drug delivery system for therapy of gastric cancer.Keywords: gastric cancer, paclitaxel, nano-lipid carriers, gastric cancer peptide, anti-tumor activityhttps://www.dovepress.com/a-gastric-cancer-peptide-gx1-modified-nano-lipid-carriers-encapsulatin-peer-reviewed-article-DDDTgastric cancerpaclitaxelnano-lipid carriersgastric cancer peptideanti-tumor activity |
| spellingShingle | Jian Y Zhao M Cao J Fan T Bu W Yang Y Li W Zhang W Qiao Y Wang J Wen A A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity Drug Design, Development and Therapy gastric cancer paclitaxel nano-lipid carriers gastric cancer peptide anti-tumor activity |
| title | A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity |
| title_full | A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity |
| title_fullStr | A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity |
| title_full_unstemmed | A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity |
| title_short | A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity |
| title_sort | gastric cancer peptide gx1 modified nano lipid carriers encapsulating paclitaxel design and evaluation of anti tumor activity |
| topic | gastric cancer paclitaxel nano-lipid carriers gastric cancer peptide anti-tumor activity |
| url | https://www.dovepress.com/a-gastric-cancer-peptide-gx1-modified-nano-lipid-carriers-encapsulatin-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT jiany agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT zhaom agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT caoj agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT fant agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT buw agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT yangy agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT liw agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT zhangw agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT qiaoy agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT wangj agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT wena agastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT jiany gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT zhaom gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT caoj gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT fant gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT buw gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT yangy gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT liw gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT zhangw gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT qiaoy gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT wangj gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity AT wena gastriccancerpeptidegx1modifiednanolipidcarriersencapsulatingpaclitaxeldesignandevaluationofantitumoractivity |